Inactive Instrument

Neuropathix, Inc. Stock price

Equities

NPTX

US64132Q1094

Biotechnology & Medical Research

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 60 18-07-24
Director of Finance/CFO 67 18-07-24
Chief Tech/Sci/R&D Officer 66 18-07-24
Members of the board TitleAgeSince
Director/Board Member 55 17-06-19
Director/Board Member 71 18-07-24
Chief Executive Officer 60 18-07-24
More insiders
Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.
More about the company
  1. Stock
  2. Equities
  3. Stock Neuropathix, Inc. - OTC Markets